Alkermes (ALKS) PT Raised to $70 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Alkermes (ALKS) PT Raised to $70 at Credit Suisse
October 21, 2016 9:29 AM EDTCredit Suisse analyst Vamil Divan reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $52.00) after the company released positive data after the close from the third Phase 3 study for their pipeline anti-depression drug ALKS-5461.
Divan... More
Alkermes (ALKS) PT Raised to $70 at Leerink Partners
October 21, 2016 6:41 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and raised its price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $57.00) after the company announced positive results from their third ph3 study for ALKS5461 in depression.
Matteis commented, "We were previously... More
JPMorgan Upgrades Alkermes (ALKS) to Overweight. PT $78
October 21, 2016 6:35 AM EDTJPMorgan upgraded Alkermes (NASDAQ: ALKS) from Neutral to Overweight with a price target of $78.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $43.51 yesterday.
... MoreAlkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint
October 20, 2016 4:01 PM EDTAlkermes plc (NASDAQ: ALKS) today announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The... More
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD
October 20, 2016 4:00 PM EDTAlkermes plc (NASDAQ: ALKS) announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The study... More
